While treating an HIV-infected lung cancer patient with the cancer drug nivolumab, a research team led by Professor Jean-Philippe Spano, head of the medical oncology department at Pitie-Salpetriere Hospital AP-HP in Paris observed a drastic and persistent decrease in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.